Beloranib hemioxalate  (Synonyms: ZGN-440 hemioxalate; ZGN-433 hemioxalate; CDK732 hemioxalate)

Beloranib (ZGN-440; CKD-732 free base) hemioxalate is a selective, irreversible inhibitor of methionine aminopeptidase MetAP2 that suppresses appetite and increases energy expenditure. Beloranib hemioxalate blocks the enzymatic cleavage of N-terminal methionine from nascent proteins by forming a covalent bond with MetAP2, thereby regulating fatty acid metabolism, adrenergic signaling, and hypothalamic NF-κB expression. Beloranib hemioxalate significantly reduces food intake, body weight, and fat accumulation, while improving glucose tolerance, insulin sensitivity, and lipid metabolism. Beloranib hemioxalate also elevates energy expenditure and fat oxidation levels, without affecting body temperature, spontaneous activity, or the inflammatory cytokine IL-1β. Beloranib hemioxalate can be used in research on obesity and hypothalamic obesity^[1][2][3].

Beloranib hemioxalate potently inhibits endothelial cell proliferation via selective inhibition of MetAP2^[2].
Beloranib hemioxalate (24 h pre-incubation; 3 h norepinephrine treatment) enhances norepinephrine-induced lipolysis in primary rat brown adipocytes, increasing glycerol release to 4- to 5-fold relative to vehicle^[3].
Beloranib hemioxalate (24 h pre-incubation) enhances norepinephrine-induced energy expenditure in primary rat brown adipocytes, increasing the %OCR AUC relative to vehicle^[3].
Beloranib hemioxalate (24 h concurrent treatment) reverses norepinephrine desensitization in primary rat brown adipocytes, sustaining ucp1 gene expression at 177-fold after 24 h of norepinephrine treatment^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Beloranib (0.1 mg/kg; subcutaneous injection; once daily; for 12 consecutive days) hemioxalate significantly reduces body weight gain, food intake, fasting insulin levels, and hypothalamic NF-κB expression, while increasing circulating α-MSH levels, in male Sprague Dawley rats with obesity induced by CMHL^[1].
Beloranib (0.1 mg/kg; subcutaneous injection; once daily; for 14 consecutive days) hemioxalate induces significant weight loss and reduces food intake by 28% in young adult male MC4rKO obese rats^[1].
Beloranib (0.1 mg/kg, subcutaneous injection, once daily for 21 consecutive days) hemioxalate induces a 10% body weight loss, reduces food intake, and improves insulin sensitivity in weight-stable aged male MC4rKO obese rats^[1].
Administration of Beloranib hemioxalate to nude mice with xenografts inhibits angiogenesis and tumorigenesis^[2].
Beloranib (1 mg/kg; subcutaneous injection; once daily; for 12 consecutive days) hemioxalate reduces body weight by 20-23% over 12 days in high-fat diet-induced obese male C57BL/6 mice^[3].
Beloranib (1 mg/kg; subcutaneous injection; once daily; for 14 consecutive days) hemioxalate reduces body weight by 22-25% within 14 days in high-fat diet-induced obese C57BL/6 mice, while decreasing fat mass and increasing lean mass, but exerts minimal effects on body weight and body composition in lean mice^[3].
Beloranib (0.3 mg/kg; subcutaneous injection; administered twice at 9:00 a.m. on Day 1 and Day 2) hemioxalate inhibits MetAP2 activity in brown adipose tissue of C57BL/6 mice with obesity induced by a high-fat diet^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1089.32

C₂₉H₄₁NO₆.1/2C₂H₂O₄

529511-79-3

C[C@]1([C@H](O1)C/C=C(C)\C)[C@]2([H])[C@]3(CC[C@H]([C@H]2OC)OC(/C=C/C4=CC=C(C=C4)OCCN(C)C)=O)CO3.O=C(O)C(O)=O.[0.5]

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Elfers CT, et al. Robust Reductions of Excess Weight and Hyperphagia by Beloranib in Rat Models of Genetic and Hypothalamic Obesity. Endocrinology. 2017;158(1):41-55.  [Content Brief]

  [2]. Hughes TE, et al. Ascending dose-controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women. Obesity (Silver Spring). 2013;21(9):1782-1788.  [Content Brief]

  [3]. Huang HJ, et al. MetAP2 inhibition increases energy expenditure through direct action on brown adipocytes. J Biol Chem. 2019;294(24):9567-9575.  [Content Brief]